MARKET

RNXT

RNXT

Renovorx Inc
NASDAQ
1.110
-0.040
-3.48%
Opening 15:39 08/07 EDT
OPEN
1.170
PREV CLOSE
1.150
HIGH
1.200
LOW
1.110
VOLUME
289.52K
TURNOVER
--
52 WEEK HIGH
1.450
52 WEEK LOW
0.7006
MARKET CAP
50.06M
P/E (TTM)
-3.3494
1D
5D
1M
3M
1Y
5Y
1D
RenovoRx Highlights TAMP Platform in Upcoming Oncology Webinar
TipRanks · 2d ago
Travere Therapeutics (TVTX) Reports Q2 Loss, Beats Revenue Estimates
NASDAQ · 2d ago
RenovoRx joins JonesTrading webinar on TAMP platform in pancreatic cancer
PUBT · 3d ago
Cue Biopharma Appoints Ahlers As CFO Following IND Filing And Pipeline Progress
NASDAQ · 3d ago
Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Beat Estimates
NASDAQ · 4d ago
Weekly Report: what happened at RNXT last week (0727-0731)?
Weekly Report · 4d ago
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), RenovoRx (RNXT) and ACADIA Pharmaceuticals (ACAD)
TipRanks · 07/30 17:30
RenovoRx to host Q2 2026 results conference call
PUBT · 07/29 12:33
More
About RNXT
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.

Webull offers RenovoRx Inc stock information, including NASDAQ: RNXT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNXT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNXT stock methods without spending real money on the virtual paper trading platform.